These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 27322850)

  • 1. Life after transplant: are we becoming high maintenance in AML?
    Brunner AM; Fathi AT; Chen YB
    Bone Marrow Transplant; 2016 Nov; 51(11):1423-1430. PubMed ID: 27322850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-transplant maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation harmonizing multiple therapeutic modalities including targeted therapy, immunotherapy and cellular therapy.
    Al-Shaibani E; Novitzky-Basso I; Mattsson J; Kim DDH
    Int J Hematol; 2023 Jul; 118(1):1-17. PubMed ID: 37212948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.
    Appelbaum FR
    Best Pract Res Clin Haematol; 2013 Sep; 26(3):279-84. PubMed ID: 24309531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous hematopoietic cell transplantation for adult acute myeloid leukemia: An obsolete or resurfacing concept?
    Lazarus HM; El Jurdi N
    Best Pract Res Clin Haematol; 2017 Dec; 30(4):327-332. PubMed ID: 29156204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention and treatment of acute myeloid leukemia relapse after allogeneic stem cell transplantation.
    Oran B; de Lima M
    Curr Opin Hematol; 2011 Nov; 18(6):388-94. PubMed ID: 21897227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance therapy for AML after allogeneic HCT.
    Nayak RK; Chen YB
    Front Oncol; 2022; 12():895771. PubMed ID: 36016625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.
    Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL
    Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Preventative and therapeutic relapse strategies after allogeneic hematopoietic stem cell transplantation: Guidelines from the Francophone society of bone marrow transplantation and cellular therapy (SFGM-TC)].
    Yafour N; Beckerich F; Bulabois CE; Chevallier P; Daguindau É; Dumesnil C; Guillaume T; Huynh A; Levrat SM; Menard AL; Michallet M; Pautas C; Poiré X; Ravinet A; Yakoub-Agha I; Bazarbachi A
    Bull Cancer; 2017 Dec; 104(12S):S84-S98. PubMed ID: 29179894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detecting and preventing post-hematopoietic cell transplant relapse in AML.
    Austin AE; Byrne M
    Curr Opin Hematol; 2021 Nov; 28(6):380-388. PubMed ID: 34534984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?
    Epperla N; Fenske TS; Lazarus HM; Hamadani M
    Bone Marrow Transplant; 2015 Nov; 50(11):1393-404. PubMed ID: 26281033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation.
    Antar A; Kharfan-Dabaja MA; Mahfouz R; Bazarbachi A
    Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):298-302. PubMed ID: 25550214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of AML Relapse After Allo-HCT.
    Webster JA; Luznik L; Gojo I
    Front Oncol; 2021; 11():812207. PubMed ID: 34976845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute myeloid leukemia: 2013 update on risk-stratification and management.
    Estey EH
    Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematopoietic cell transplantation for adults with acute myeloid leukemia with minimal residual disease.
    Appelbaum FR
    Best Pract Res Clin Haematol; 2015; 28(2-3):133-40. PubMed ID: 26590770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.
    Qin YZ; Wang Y; Zhu HH; Gale RP; Zhang MJ; Jiang Q; Jiang H; Xu LP; Chen H; Zhang XH; Liu YR; Lai YY; Jiang B; Liu KY; Huang XJ
    Chin J Cancer; 2016 May; 35():46. PubMed ID: 27197573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance therapies in acute myeloid leukemia: the renaissance of an old therapeutic concept.
    Bewersdorf JP; Tallman MS; Stahl M
    Curr Opin Oncol; 2021 Nov; 33(6):658-669. PubMed ID: 34341323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance therapy in AML: The past, the present and the future.
    Molica M; Breccia M; Foa R; Jabbour E; Kadia TM
    Am J Hematol; 2019 Nov; 94(11):1254-1265. PubMed ID: 31429099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AML in 2017: Advances in clinical practice.
    Rowe JM
    Best Pract Res Clin Haematol; 2017 Dec; 30(4):283-286. PubMed ID: 29156195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in hematopoietic cell transplant for the treatment of hematologic malignancies.
    Taraseviciute A; Pulsipher MA
    Curr Opin Pediatr; 2019 Feb; 31(1):3-13. PubMed ID: 30585866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with improved outcomes after second allogeneic hematopoietic cell transplantation for relapsed pediatric leukemia.
    Menon NN; Jenkins LM; Cui H; Jenkins C; Anwer F; Yeager AM; Katsanis E
    Ann Hematol; 2016 Mar; 95(4):637-44. PubMed ID: 26787415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.